Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Resources for healthcare professionals
Expert lead video content, congress highlights and downloadable resources for healthcare professionals about ovarian cancer.
PARPi: What pharmacists need to know in the changing advanced ovarian cancer (AOC) landscape (presented at BOPA 2021) (43 mins)
Dr Pinkie Chambers, Dr John McGrane, Ms Alicia Salisbury
Evaluating the new first-line maintenance treatment options in AOC – who should get what? (presented at BGCS virtual meeting 2021) (5 mins)
Dr Susana Banerjee
The role of HRD testing and the challenges of COVID-19 in advanced ovarian cancer treatment (11 mins)
Professor Jonathan Ledermann, Professor Marcia Hall
How is COVID-19 affecting the treatment and management of ovarian cancer? (53 mins)
Professor Jonathan Ledermann, Dr Rebecca Bowen,Christina Fotopoulou, Professor Marcia Hall
Link to prescribing information can be found at the top of this page.
ZEJULA is indicated1
- as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- as monotherapy for the maintenance treatment of adult patients with platinumsensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Footnotes
AOC, advanced ovarian cancer; BGCS, British Gynaecological Cancer Society; BOPA, British Oncology Pharmacy Association; HCP, healthcare professional; HRD, homologous recombination deficiency; MoA, mechanism of action; PARPi, poly (ADP-ribose) polymerase inhibitors; QoL, quality of life; SMC, Scottish Medicines Consortium
References
- ZEJULA Summary of Product Characteristics.
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store.
Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
March 2022 | PM-GB-NRP-WCNT-210023 (V1.0)
